Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefalexin -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - phenoxymethylpenicillin benzathine -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - potassium clavulanate, quantity: 7.4 mg/ml (equivalent: clavulanic acid, qty 6.25 mg/ml); amoxicillin trihydrate, quantity: 28.7 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; hypromellose; aspartame; succinic acid; xanthan gum; colloidal anhydrous silica; flavour - augmentin is indicated in the treatment of the following infections when caused by augmentin sensitive, beta-lactamase producing organisms: skin and skin structure infections, including cases caused by beta-lactamase producing s. aureus, e. coli and klebsiella spp. (only some strains may be sensitive). urinary tract infections, including cases caused by beta-lactamase producing e. coli, p. mirabilis & klebsiella spp. upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing h.influenzae and m.catarrhalis, and otitis media, especially cases caused by beta-lactamase producing h. influenzae, m. catarrhalis and s. aureus. lower respiratory tract infections, especially cases caused by beta-lactamase producing h.influenzae and m.catarrhalis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin should not require the addition of another antibiotic due to the amoxicillin content of augmentin.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate -

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - carbamazepine - oral suspension - 20mg/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - carbamazepine - oral suspension - 20mg/1ml